Health/Pharmaceuticals
Synthetic Psilocybin Shows Major Breakthrough in Trials for Treatment‑Resistant Depression🔥67
2/19/2026•Health > Pharmaceuticals
- •Developed by mental health biotech firm Compass Pathways.
- •Trials focused on treatment-resistant depression (TRD) patients.
- •25 mg dose significantly reduced symptoms on the MADRS scale.
- •Mean difference of -3.8 points vs. 1 mg control at week six.
FDA Reconsiders Moderna’s mRNA Flu Shot, Moves Forward With Approval Review🔥66
2/18/2026•Health > Pharmaceuticals
- •The agency will now review the candidate, mRNA-1010, for possible approval.
- •Moderna had faced delays after the FDA initially raised efficacy concerns.
- •The vaccine uses mRNA technology similar to Moderna’s COVID-19 shot.
- •It targets four main influenza strains recommended annually by the WHO.
Innovent and Takeda Forge $11.4 Billion Global Alliance to Advance Next-Generation Cancer Therapies🔥55
10/21/2025•Health > Pharmaceuticals
- •Innovent receives \$1.2 billion upfront and a \$100 million equity investment at a 20% premium.
- •Up to \$10.2 billion in milestone payments are tied to development, regulatory, and sales goals.
- •The deal focuses on two late-stage cancer drugs: IBI363 and IBI343.
- •IBI363 is a PD-1/IL-2 bispecific antibody improving tumor immune response with fewer side effects.
